Picture EBD Group Global Partnering Four Events One Price 650x80
Document › Details

BiomX Ltd.. (5/15/17). "Press Release: BiomX Raises $24 Million in Series A Funding to Develop Microbiome Therapeutics". Ness Ziona.

Organisations Organisation BiomX Ltd.
  Group BiomX (Group)
  Organisation 2 OrbiMed Israel Incubator LP
  Group OrbiMed (Group)
Products Product microbiomic treatment (live biotherapeutic product, LBP)
  Product 2 venture capital
Index terms Index term BiomX–SEVERAL: investment, 201705 financing round Series A $24m led by OrbiMed + JJDC Inc + Takeda Ventures
  Index term 2 BiomX–JnJ: investment, 201705 financing round Series A totalling $24m incl co-lead investor JnJ Innovation JJDC Inc
Persons Person Solomon, Jonathan (BiomX 201705 CEO before Proclara/NeuroPhage 201403 CEO before Israeli military)
  Person 2 Granot-Mayer, Gil (Weizmann Institute 201405 Deputy CEO + General Counsel at Yeda RnD)

Funds will be used for advancing Company’s novel therapeutic pipeline and enhancing its unique microbiome modulation platform technologies

BiomX Ltd., a leading microbiome therapeutics company, announced today that it has successfully secured $24 million in a Series A financing. The round was led by OrbiMed, Johnson & Johnson Innovation – JJDC, Inc. and Takeda Ventures, Inc. with participation from Seventure Partners, MiraeAsset, SBI Japan-Israel Innovation Fund and other European investors. Proceeds from the round will be used to advance the Company’s novel therapeutic pipeline towards clinical stages and to continue enhancing its proprietary microbiome modulation platform technologies. BiomX, previously named MBcure, was founded in the FutuRx Ltd. incubator, with the support of the Israel Innovation Authority.

“We are fortunate to have such exceptional strategic investors support us and our vision of developing novel therapies for unmet medical needs based on our proprietary understanding and modulation of the microbiome,” stated Jonathan Solomon, CEO of BiomX. “We are committed to utilize our technological capabilities for the accelerated development of our pipeline towards clinical stage products.”

BiomX focuses on developing novel therapeutics to alleviate human diseases stemming from dysbiosis of the microbiome. The Company offers a complete end-to-end solution from target discovery to development of therapeutic compounds, with flexible capabilities to precisely modulate the microbiome and restore microbial balance through adding or eradicating bacteria with both native and synthetically altered phages (viruses that attack bacteria). BiomX’s microbiome modulation technologies are based on the pioneer science and research of its scientific collaborators: Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology. The Company’s therapeutic pipeline consists of products for the treatment of acne, Inflammatory Bowel Disease (IBD), cancer, and therapeutics that modulate the microbiome for improved performance of immuno-oncology drugs.

Anya Eldan, General Manager, Start-Up Division, Israel Innovation Authority, commented, “The Israel Innovation Authority’s support of risky early-stage projects with large potential enables establishment of such a promising company at the forefront of delivering microbiome therapeutics.” Einat Zisman, PhD, CEO of FutuRx, added, “This investment reflects FutuRx’s role in establishing and supporting start-up companies that turn break-through technologies into innovative therapeutics. Such support enables FutuRx’s portfolio companies to build strategic collaborations and compete in the global market.”

Gil Granot Mayer, CEO of Yeda, the commercialization arm of the Weizmann Institute of Science, responded, ”This is yet another example of the scientific excellence that prevails at the Weizmann institute of Science and of the ability of Yeda to effectively commercialize this scientific excellence towards life-changing products.”

About The Microbiome

The microbiome, all the bacteria that reside in and on the human body, is an exciting and fast-developing new field at the interface of pharmaceuticals and nutrition, offering abundant opportunities for developing new medicines. The composition of bacteria forming the microbiome, mainly gut bacteria, has been linked to various health conditions, from acne and allergies, through gastrointestinal ailments, obesity and cancer. The multitude of biological processes and indications affected by the microbiome make the bacteria in the human microbiome critical to health, yet the microbiome’s diversity presents a challenge for identifying specific targets and developing new medicines to treat imbalance of the microbiome.

About BiomX

BiomX discovers and develops innovative microbiome therapeutics. The Company’s mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX’s microbiome modulation technologies are based on the cutting-edge innovative research of its scientific collaborators: Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology. For additional information, please visit

Company contact:
Assaf Oron
Chief Business Officer

Media contact:
Tsipi Haitovsky
Global Media Liaison

Record changed: 2019-03-09


Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for BiomX (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] Back into Ad 650x80px

» top